Engineered t cells take on ovarian cancer in new trial

NCT ID NCT03184753

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests a new treatment for advanced ovarian cancer using a patient's own immune cells, called T cells, that are modified in a lab to better recognize and attack the cancer. About 100 women with stage III or IV ovarian cancer will receive these modified cells. The main goals are to check safety and see if the cells can trigger an anti-cancer response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OC-IgT cells (a patient's own immune cells modified to target ovarian cancer)
What this could lead to: If successful, this could point toward a new treatment option for advanced ovarian cancer that uses the patient's own immune system.
What could go wrong: This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. The treatment may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.